China Resources Pharmaceutical announced that its subsidiary listed company, Kunyao Group, expects net profit attributable to shareholders of listed companies to lose 330 million yuan to 400 million yuan in the first half of 2026, compared to profit of 198 million yuan for the same period last year, changing from profit to loss; net profit loss after deducting non-recurring profit and loss of 350 million yuan to 430 million yuan, and profit of 151 million yuan for the same period last year. The decline in performance was mainly affected by internal and external factors such as the tightening of pharmaceutical industry policies, in-depth market environment adjustments, and the optimization of its own channel structure and business model transformation.

China Resources Pharmaceutical announced that its subsidiary listed company, Kunyao Group, expects net profit attributable to shareholders of listed companies to lose 330 million yuan to 400 million yuan in the first half of 2026, compared to profit of 198 million yuan for the same period last year, changing from profit to loss; net profit loss after deducting non-recurring profit and loss of 350 million yuan to 430 million yuan, and profit of 151 million yuan for the same period last year. The decline in performance was mainly affected by internal and external factors such as the tightening of pharmaceutical industry policies, in-depth market environment adjustments, and the optimization of its own channel structure and business model transformation.